These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 24325991)

  • 1. Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBDs): What the Endocrinologist Needs to Know.
    Zangeneh F; Clarke BL; Hurley DL; Watts NB; Miller PD
    Endocr Pract; 2014 May; 20(5):500-16. PubMed ID: 24325991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoporosis management in patient with renal function impairment.
    Lima GA; Paranhos Neto Fde P; Pereira GR; Gomes CP; Farias ML
    Arq Bras Endocrinol Metabol; 2014 Jul; 58(5):530-9. PubMed ID: 25166044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification.
    Fang Y; Ginsberg C; Sugatani T; Monier-Faugere MC; Malluche H; Hruska KA
    Kidney Int; 2014 Jan; 85(1):142-50. PubMed ID: 23884339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating the causes of adynamic bone in advanced chronic kidney disease informs osteoporosis treatment.
    Haarhaus M; Evenepoel P; ;
    Kidney Int; 2021 Sep; 100(3):546-558. PubMed ID: 34102219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].
    Omata M; Fukagawa M; Kakuta T
    Clin Calcium; 2015 May; 25(5):645-53. PubMed ID: 25926567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The demise of calcium-based phosphate binders-is this appropriate for children?
    Rees L; Shroff R
    Pediatr Nephrol; 2015 Dec; 30(12):2061-71. PubMed ID: 25543193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of phosphate binders: a perspective on novel therapeutics.
    Cernaro V; Santoro D; Lucisano S; Nicocia G; Lacquaniti A; Buemi M
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1459-63. PubMed ID: 25243756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New Developments in CKD-MBD. New aspects in phosphate binders].
    Yokoyama K
    Clin Calcium; 2014 Dec; 24(12):1815-23. PubMed ID: 25423927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease.
    Hampson G; Elder GJ; Cohen-Solal M; Abrahamsen B
    Endocrine; 2021 Sep; 73(3):509-529. PubMed ID: 33974225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of bone in CKD-mediated mineral and vascular disease.
    Khouzam NM; Wesseling-Perry K; Salusky IB
    Pediatr Nephrol; 2015 Sep; 30(9):1379-88. PubMed ID: 25168424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
    Iwashita Y; Iwashita Y; Ito T; Shigematsu T
    Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
    Bover J; Ureña-Torres P; Lloret MJ; Ruiz C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
    Expert Opin Pharmacother; 2016 Jul; 17(10):1363-73. PubMed ID: 27156578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation.
    Pimentel A; Ureña-Torres P; Zillikens MC; Bover J; Cohen-Solal M
    Kidney Int; 2017 Dec; 92(6):1343-1355. PubMed ID: 28964571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality.
    Block GA
    Curr Opin Nephrol Hypertens; 2011 Jul; 20(4):376-81. PubMed ID: 21519253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease and fragility fracture.
    Kazama JJ
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):46-52. PubMed ID: 28012057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series.
    Amerling R; Harbord NB; Pullman J; Feinfeld DA
    Blood Purif; 2010; 29(3):293-9. PubMed ID: 20090316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.